| Target Price | €38.76 |
| Price | €29.76 |
| Potential |
30.24%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Huhtamäki 2026 .
The average Huhtamäki target price is €38.76.
This is
30.24%
register free of charge
€46.20
55.24%
register free of charge
€28.28
4.97%
register free of charge
|
|
| A rating was issued by 22 analysts: 18 Analysts recommend Huhtamäki to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Huhtamäki stock has an average upside potential 2026 of
30.24%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 4.13 | 4.17 |
| 1.02% | 0.94% | |
| EBITDA Margin | 9.31% | 15.46% |
| 3.54% | 66.13% | |
| Net Margin | 5.43% | 6.40% |
| 9.75% | 17.84% |
16 Analysts have issued a sales forecast Huhtamäki 2025 . The average Huhtamäki sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Huhtamäki EBITDA forecast 2025. The average Huhtamäki EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Huhtamäki Analysts have issued a net profit forecast 2025. The average Huhtamäki net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.14 | 2.54 |
| 8.63% | 18.69% | |
| P/E | 11.72 | |
| EV/Sales | 1.06 |
16 Analysts have issued a Huhtamäki forecast for earnings per share. The average Huhtamäki EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


